Extension Study To Assess Batoclimab In Participants With Thyroid Eye Disease

Overview

About this study

The purpose of the observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the effectiveness of batoclimab as assessed by proptosis responder rate.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - For All Participants:

  • Have completed the Week 24 visit of the feeder study.

Inclusion Criteria - For Participants Assigned to the Open-label Treatment Cohort:

  • Do not require immediate surgical intervention and is not planning corrective surgery/irradiation or medical therapy for TED during the course of the study.
  • Did not permanently discontinue batoclimab.

Exclusion Criteria - For All Participants:

  • In the Investigator's judgement, the benefits of entry in the study do not outweigh the risk.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/30/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Marius Stan, M.D.

Open for enrollment

Contact information:

Hamad Gul

5072845833

gul.hamad@mayo.edu

More information

Publications

Publications are currently not available